



Diversified Consumer Services | Small Cap
Maitreya Medicare Ltd demonstrates a mixed financial performance. The company shows strong profitability and solvency, indicating efficient management of resources and a healthy balance between debt and equity. Liquidity is also reasonably strong, suggesting the company can meet its short-term obligations. However, growth metrics are inconsistent, with revenue and asset growth contrasted by declines in operating profit and earnings per share. Efficiency ratios present a mixed picture, with high inventory turnover offset by slow collection of receivables. These factors suggest opportunities for improvement in operational efficiency and earnings consistency. Overall, the company exhibits a solid financial foundation, but needs to address areas of inconsistent growth and efficiency to enhance long-term sustainability.
Maitreya Medicare Ltd demonstrates a mixed financial performance. The company shows strong profitability and solvency, indicating efficient management of resources and a healthy balance between debt and equity. Liquidity is also reasonably strong, suggesting the company can meet its short-term obligations. However, growth metrics are inconsistent, with revenue and asset growth contrasted by declines in operating profit and earnings per share. Efficiency ratios present a mixed picture, with high inventory turnover offset by slow collection of receivables. These factors suggest opportunities for improvement in operational efficiency and earnings consistency. Overall, the company exhibits a solid financial foundation, but needs to address areas of inconsistent growth and efficiency to enhance long-term sustainability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-61.48
Industry Median
53.17
Small Cap Median
50.07
P/E RATIO
-33.01
P/B RATIO
2.82
Industry Median
5.27
Small Cap Median
3.62
P/S RATIO
1.77
Industry Median
3.91
Small Cap Median
2.08
Others
PEG RATIO
0.00
EV/EBITDA RATIO
175.09
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹120.5 as on Sep 1, 2026.
The company exhibits mixed growth performance. While revenue and asset growth are positive, declines in operating profit and earnings per share raise concerns about profitability sustainability. Stabilizing and improving earnings growth will be critical for future investor confidence. Diversifying revenue streams can help.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -11.76 | -20.41 | 17.31 | -2.39 | -0.29 |
| Operating Profit Growth Rate | -53.52 | 115.43 | -17.36 | -18.67 | -109.43 |
| Earnings Per Share (EPS) Growth | -73.11 | -99.25 | -48.89 | -36.99 | -232.25 |
| Asset Growth Rate | -3.09 | 18.05 | 51.71 | 9.44 | 42.58 |
| Net Income Growth Rate | -73.11 | 272.81 | -30.12 | -37.04 | -232.09 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Maitreya Medicare Ltd | 7.34 | -33.01 | Neutral | -0.46 | -1.96 | -2.47 |
| 2 | Sangani Hospitals Ltd | 7.21 | 24.19 | Neutral | 8.00 | 1.74 | 4.00 |
| 3 | Lotus Eye Hospital & Institute Ltd | 6.07 | 328.53 | Overvalued | 3.38 | 0.04 | 0.08 |
| 4 | Nephro Care India Ltd | 5.69 | 43.87 | Neutral | 8.32 | 2.04 | 3.37 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Maitreya Medicare Ltd. operates a 120-bed multi-specialty hospital in Surat, Gujarat, offering comprehensive healthcare services. The company provides advanced medical care across various disciplines including cardiology, oncology, and neurology. It positions itself as a regional healthcare provider focused on accessible and affordable treatment solutions.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Maitreya Medicare Ltd's P/E ratio (TTM) is -61.48, compared to the industry median of 53.17 and large cap median of 50.07.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Maitreya Medicare Ltd's P/B ratio is 2.82, compared to the industry median of 5.27 and large cap median of 3.62.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Maitreya Medicare Ltd's P/S ratio is 1.77, compared to the industry median of 3.91 and large cap median of 2.08.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Maitreya Medicare Ltd's PEG ratio is 1.10.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Maitreya Medicare Ltd's EV/EBITDA ratio is 175.09.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Maitreya Medicare Ltd's ROE is -8.51%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Maitreya Medicare Ltd's ROA is -0.67%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Maitreya Medicare Ltd's ROCE is -2.18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Maitreya Medicare Ltd's operating margin is -1.03%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Maitreya Medicare Ltd's net margin is -5.51%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Maitreya Medicare Ltd's current ratio is 1.58.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Maitreya Medicare Ltd's debt-to-equity ratio is 0.75.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Maitreya Medicare Ltd's interest coverage ratio is -0.67.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Maitreya Medicare Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Maitreya Medicare Ltd's EPS is -232.25.
(Source line: "Ratios as of 22 Nov 2026, based on last traded price of ₹120.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2019
Headquarters: Surat, Gujarat
Core Offerings: Cardiology, Oncology, Neurology, Orthopedics, Critical Care
Stock Listing: NSE (MAITREYA), BSE ({bse})
Promoter: Dr. Narendra Singh Tanwar and Dr. Chitrakshi Tanwar
Maitreya Medicare Ltd. was incorporated in 2019 with a vision to deliver quality healthcare services. The company quickly established its 120-bed multi-specialty hospital in Surat, Gujarat. Focused on providing a wide array of medical and surgical treatments, it successfully completed its Initial Public Offering (IPO) in October 2023, listing on the NSE Emerge platform, marking a significant step in its expansion journey.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Multi-specialty Hospital Services | 100% | Operating Profit |
Dr. Narendra Singh Tanwar (Chairman & Managing Director): A highly experienced medical professional and founder, instrumental in establishing the hospital and driving its strategic growth and operational excellence with a strong focus on patient care.
No major subsidiaries reported.
The company successfully completed its IPO and listed on NSE Emerge in October 2023. No other major recent corporate actions on record.
The Maitreya Medicare Ltd share price today is ₹120.50 on NSE (MAITREYA), as of 22 Nov 2026.
As of 22 Nov 2026, Maitreya Medicare Ltd share price is ₹120.50, with previous close ₹120.50. Today's range is ₹120.50 to ₹120.50. The 52-week range is ₹N/A to ₹N/A.
As of today, Maitreya Medicare Ltd's market cap is ₹79.53 crore (Small Cap).
Maitreya Medicare Ltd's current P/E ratio is -61.48, compared to the DIVERSIFIED CONSUMER SERVICES sector average of 61.10.
Maitreya Medicare Ltd's current P/B ratio is 2.82.
Maitreya Medicare Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Maitreya Medicare Ltd's EPS (TTM) is ₹-232.25.
Maitreya Medicare Ltd. operates a 120-bed multi-specialty hospital in Surat, Gujarat, offering comprehensive healthcare services. The company provides advanced medical care across various disciplines including cardiology, oncology, and neurology. It positions itself as a regional healthcare provider focused on accessible and affordable treatment solutions.
Maitreya Medicare Ltd is promoted by Dr. Narendra Singh Tanwar and Dr. Chitrakshi Tanwar, holding 73.11% as of 22 Nov 2026.
Maitreya Medicare Ltd is listed on NSE (MAITREYA) and BSE ({bse}). Its next quarterly results are expected on Q1 FY25 results around August 2024.